MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
-0.51 (-0.62%)
At close: 4:00PM EDT

81.75 +0.20 (0.25%)
After hours: 5:16PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close82.06
Bid81.56 x 800
Ask81.99 x 1000
Day's Range80.84 - 82.16
52 Week Range65.25 - 92.64
Avg. Volume13,119,514
Market Cap205.84B
Beta (5Y Monthly)0.53
PE Ratio (TTM)22.79
EPS (TTM)3.58
Earnings DateJul 31, 2020
Forward Dividend & Yield2.44 (2.97%)
Ex-Dividend DateJun 12, 2020
1y Target Est93.59
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
3% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • MarketWatch

    Johnson & Johnson, UnitedHealth share losses lead the way, but Dow flat

    DOW UPDATE Shares of Johnson & Johnson and UnitedHealth are trading lower Thursday morning, dragging the Dow Jones Industrial Average into negative territory. Shares of Johnson & Johnson (JNJ) and UnitedHealth (UNH) have contributed to the blue-chip gauge's intraday decline, as the Dow (DJIA) was most recently trading 12 points, or 0.


    Gates Pledges $1.6 Billion for Vaccines. What That Means for Covid-19 and Other Diseases.

    The Bill and Melinda Gates Foundation is pledging $1.6 billion to a global organization that provides vaccines to children in the poorest countries.

  • 5 Promising Covid-19 Vaccines Now Selected For Trump’s Operation Warp Speed

    5 Promising Covid-19 Vaccines Now Selected For Trump’s Operation Warp Speed

    Five companies have now been picked by the Trump administration as the most likely candidates to produce a coronavirus vaccine, The New York Times reports.This comes as part of Operation Warp Speed (OWS), the administration’s national program to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.Among its other objectives, Operation Warp Speed aims to have substantial quantities of a safe and effective vaccine available for Americans by January 2021.The five companies selected are as follows:Moderna’s (MRNA) mRNA1273 which is currently undergoing Phase 2 trials;A joint collaboration between AstraZeneca (AZN) and Oxford University on AZD1222 which is now in clinical trials at multiple UK sites;Johnson & Johnson (JNJ) which plans to start a Phase 1 clinical trial in September with an ultimate goal of supplying more than one billion doses of its coronavirus vaccine globally;Merck (MRK) which is trying to develop a vaccine using similar technology to its successful Ebola vaccine through a partnership with non-profit research organization IAVI, and;Pfizer (PFE) is working with German drugmaker BioNTech (BNTX) on clinical trials of BNT162, with plans to have a vaccine ready by the end of October, and produce “hundreds of millions” of doses in 2021.GlaxoSmithKline and Sanofi did not make the cut.On May 15 Operation Warp Speed revealed plans to select the most promising countermeasure candidates and provide coordinated government support to support their development.Large-scale randomized trials for the demonstration of safety and efficacy will proceed for three to five of the candidates, with as many as 150,000 people vaccinated if all five vaccine candidates reach the Phase 3 stage.Indeed, Congress has directed almost $10 billion to this effort through supplemental funding, including the CARES Act, with $3 billion directed for NIH research.“Vaccines are coming along really well,” President Trump told the Twittersphere on Tuesday. “Moving faster than anticipated. Good news ahead.”Shares in Moderna have exploded over 200% year-to-date, and optimism continues to rise after the company recently announced that it has started dosing the first patients in a Phase 2 study with its experimental mRNA-1273 vaccine candidate.The Phase 2 study, being conducted by Moderna under its own Investigational New Drug (IND) application, seeks to evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart. The biotech company plans to enroll 600 healthy participants across two cohorts of adults ages 18-55 years and older adults ages 55 years and above.Earlier this month, Moderna reported “positive” interim clinical data saying that the Phase 1 study of its mRNA-1273 vaccine candidate produced antibodies that would be able to “neutralize” the virus in patients. The company reiterated plans to start the Phase 3 trial in July, subject to the finalization of the clinical trial protocol.Five-star analyst Cory Kasimov at J.P. Morgan recently reiterated a Buy rating on the stock, saying “How to appropriately capture this in MRNA’s valuation is a tough question to answer (especially given all the unknowns around COVID-19 and the ultimate opportunity) and one that we suspect will be a key investor debate going forward.”Overall, Wall Street analysts are bullish on Moderna stock with 10 Buy and 2 Hold ratings giving it a Strong Buy consensus. Despite the recent rally, the $89.33 average price target still indicates 50% upside potential from current levels. (See Moderna stock analysis on TipRanks).Related News: Gilead Sinks 3% On New Remdesivir Data; Analysts Stay Sidelined Pfizer Loses 6% On Disappointing Ibrance Breast Cancer Outcome Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses More recent articles from Smarter Analyst: * 3 Under-The-Radar Cannabis Stocks Ready to Bounce * AstraZeneca Seeks To Make 2 Billion Covid-19 Vaccine Doses With New Supply Deals * Ebay Lifts Quarterly Sales and Profit Forecast; Shares Jump To All-Time High * 3 “Strong Buy” Penny Stocks That Could See Outsized Returns

  • Benzinga

    Traders Share Their Health Care Picks

    On CNBC's "Trading Nation," Mark Tepper of Strategic Wealth Partners and Mark Newton of Newton Advisors spoke about opportunities in the health care sector.Tepper likes Bristol-Myers Squibb Co (NYSE: BMY). The stock has been a laggard, but that's what he's looking for since the sector was one of the top performers since the beginning of the crisis. He sees the stock as a pure play on cancer, which is the top medical problem in the world. It's trading at 10 times forward earnings, with a PEG ratio of less than one and it has a strong pipeline, said Tepper.Newton is a buyer of Merck & Co., Inc. (NYSE: MRK). It has been underperforming, but now it's showing some real technical strength. It broke above its downtrend line, but it's still 10% under its highs. The pullback that we have seen in the last few months has not undercut its long-term uptrend, said Newton. He expects the stock to get back up, towards $92.See more from Benzinga * Cramer Shares His Thoughts On Teva, Oxford Industries And More * Fast Money Picks For April 27 * Cramer Weighs In On Uber, Yelp And More(C) 2020 Benzinga does not provide investment advice. All rights reserved.

  • MarketWatch

    NYT: Trump identifies five drugmakers most likely to produce a viable COVID-19 vaccine

    The Trump administration has reportedly named five drugmakers that it expects to be the most likely to produce a viable COVID-19 vaccine, according to The New York Times, which cited people familiar with the matter. This includes AstraZeneca in combination with Oxford University, Johnson & Johnson , Moderna Inc. , Merck & Co. Inc. , and Pfizer in combination with BioNTech SE . With the exception of Merck, Pfizer, and BioNTech, shares of those companies were up in afternoon trading on Wednesday. Inovio Pharmaceuticals Inc. , an early vaccine contender, was not included in the Times' report. Its stock was down 10.8%. Much of the nation's hopes for an economic recovery are tied to the development of a vaccine that can successfully prevent people from becoming infected with COVID-19. The administration has tirelessly promoted the idea that a vaccine can be developed by the end of the year; however, executives at J&J and Merck have pointed out that the research and development process can take years to develop a safe, efficacious vaccine. Merck CEO Ken Frazier recently told the Financial Times a 12- to 18-month timeline is "very aggressive."

  • Reuters

    Vaccine group plans advance market agreement for COVID-19 vaccines

    The GAVI vaccines alliance is to launch an Advance Market Commitment (AMC) for future COVID-19 vaccines which it says will help secure access to the new shots for poorer countries. The AMC mechanism should provide incentives to vaccine manufacturers to invest in large scale production capacity even as they develop new products and before full-scale trials have shown whether they work, GAVI's chief executive officer Seth Berkley told Reuters. In return GAVI will agree to buy large quantities of vaccines at established and equitable prices to ensure initial doses are not immediately snapped up by rich countries.

  • Pharma Large And Mid-Caps Race Against COVID-19

    Pharma Large And Mid-Caps Race Against COVID-19

    COVID-19 coronavirus made us realize that health should always be our top priority. Here are some companies working to make the world a better place after the pandemic. AbbVie Inc - Botox To The Rescue With unappreciated potential, the stock of this big drugmaker has stellar fundamentals. AbbVie Inc's (NYSE: ABBV) acquisition of Allergan brought the company over 120 additional products that generated more than $16 billion in revenues last year.There were a few bumps along the way, but AbbVie now has Botox, and sales are growing in cosmetics and therapeutics.J&J - Active On All Fronts Although Johnson & Johnson (NYSE: JNJ)'s share price is nearly where it was at the start of the year, there are many reasons why this stock is an 'evergreen' favorite. To start, it is the largest healthcare company in the world with tremendous resources.In March, it committed more than $1 billion to develop a COVID-19 vaccine. It is also setting up a manufacturing capacity to produce the vaccine even before clinical trials take place by September. The vaccine could be available for emergency use authorization by 2021 if all goes well, but its scientists are exploring the potential for existing drugs to treat COVID-19.One of the main reasons that this stock has been a favorite among investors is its diversification across the healthcare sector with three business segments. The company's pharmaceutical segment is its biggest growth driver but the other two segments, consumer health, and medical devices are also multibillion-dollar businesses.Merck - Entering The COVID-19 Arena Merck & Co Inc (NYSE: MRK) announced 3 deals to find new medicines and vaccines to help combat the coronavirus. What is also positive is that Merck grew its EBIT by 29% in the last year, and that should make it easier to pay down debt.Roche - Combining Drugs To Fight COVID-19 Roche Holding AG (OTC: RHHBY) announced it plans to test whether mixing the anti-inflammation drug Actemra, with anti-viral treatment remdesivir, might give better results in treating severe cases of COVID-19 pneumonia than remdesivir alone.Roche is hoping that by combining the two in a global study of 450 hospitalized patients worldwide, it will be able to offer doctors a one-two punch against the enemy that took 360,000 lives as it quickly contaminated 5.8 million people.Everyone is fighting for the same goal - and the world is cheering for them to reach the finish line as soon as possible!This article is not a press release and is contributed by Ivana Popovic who is a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. Ivana Popovic does not hold any position in the mentioned companies. Press Releases - If you are looking for full Press release distribution contact: Contributors - IAM Newswire accepts pitches. If you're interested in becoming an IAM journalist contact: Questions about this release can be sent to ivana@iamnewswire.comPhoto by Chokniti Khongchum from Pexels.See more from Benzinga * 4 Blue Chips That Lived Up To Their Title During the Pandemic * How Social Media Stocks Fared During The Pandemic * HP and Dell At Least Managed to Top Estimates(C) 2020 Benzinga does not provide investment advice. All rights reserved.

  • 3 Pet Med Stocks That Offer Growth and a Nice Dividend
    Motley Fool

    3 Pet Med Stocks That Offer Growth and a Nice Dividend

    Spending on pet health continues to climb. Investors should consider buying PetMed Express, Phibro Animal Health, and Merck & Co.


    AstraZeneca Ranked Most Inventive, Roche Most Innovative

    AbbVie was 2 in innovation for the second consecutive year and 7 in invention Continue reading...

  • Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

    Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day

    Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day


    Buy Lilly, AbbVie and Merck Stocks, J.P. Morgan Says, but Pfizer Is Still Expensive

    Pharmaceutical stocks were early winners off the market’s March bottom, but they have lagged behind the peppy tape lately.

  • 2 “Strong Buy” Healthcare Stocks That Offer Massive Potential Gains
    Insider Monkey

    2 “Strong Buy” Healthcare Stocks That Offer Massive Potential Gains

    Antipodes Partners recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Antipodes Global Fund posted a return of -5.3% for the quarter, outperforming its benchmark, the MSCI AC World Net Index which returned -9.7% in the same quarter. You should check out Antipodes Partners top 5 stock picks […]

  • MarketWatch

    Dow flat despite losses for shares of Pfizer, Cisco

    DOW UPDATE In spite of negative returns for shares of Pfizer and Cisco, the Dow Jones Industrial Average is nearly flat Monday morning. Shares of Pfizer (PFE) and Cisco (CSCO) account for -13% of the index's intraday losses, as the Dow (DJIA) was most recently trading 2 points lower (0.


    Moderna’s Covid-19 Vaccine Enters Next Phase of Testing. Goldman Sachs Is Upbeat.

    The biotech company has dosed the first volunteers in the next phase of testing for its vaccine against the Covid-19 virus.

  • LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for First-Line Maintenance Treatment of Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer
    Business Wire

    LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for First-Line Maintenance Treatment of Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer

    LYNPARZA Receives Positive Opinion from EU CHMP for First-Line Maintenance of Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer

  • Cancer Summit Presses Toward Treatments in Covid’s Shadow

    Cancer Summit Presses Toward Treatments in Covid’s Shadow

    (Bloomberg) -- The year’s biggest meeting of cancer researchers was subjected to a coronavirus overhaul this year, but even in scaled-back form it forced investors to recalibrate their expectations for some closely watched medicines.The American Society of Clinical Oncology meeting is the field’s most important gathering each spring, providing a stage for major pharmaceutical companies to unveil major findings and tout promising treatments. It’s also an annual opportunity for all kinds of researchers, doctors, executives and investors to rub elbows.With Covid-19 making travel uncomfortable and splashy conferences impossible this year, the summit was mostly a virtual affair. Still, it delivered many of the kinds of important victories and stinging setbacks it often does. And the meeting showed that even as the drug industry races to identify virus treatments and vaccines, cancer remains perhaps its most important business overall.“When the coronavirus wanes and we have a vaccine, and this infectious disease is brought under control, we will still have cancer and the need for new treatments,” said Richard Schilsky, ASCO’s chief medical officer, in an interview. “We have millions of patients around the world who need new and improved treatments for cancer.”Among the most noteworthy winners was U.K. pharmaceutical giant AstraZeneca Plc, which reported that its blockbuster Tagrisso reduced the risk of dying from lung cancer or relapse by four-fifths over three years. The drug is already AstraZeneca’s biggest product, bringing in $982 million in sales in the first quarter alone.Some smaller drug companies also logged what looked like significant victories: Trillium Therapeutics Inc. said that a second patient taking its experimental lymphoma therapy responded to the treatment. Shares of Trillium, which has a market value of about $560 million, surged more than 17% on FridayAnd as ASCO played out, other big cancer-research news also roiled drugmaker stocks.Pfizer Inc. shares fell 5.1% in trading before U.S. exchanges opened Monday after the U.S. drug bellwether said a late-stage study of its treatment for metastatic breast cancer, Ibrance, was unlikely to show a statistically significant improvement in invasive disease-free survival for patients with early breast cancer.Though the Covid-19 pandemic has been the defining story of the health-care business this year, the ASCO meeting was a reminder that most of the world’s pharmaceutical companies remain keenly focused on finding new cancer treatments to generate profits. And that focus has paid off for patients: The U.S. death rate from cancer has been falling at a record pace, thanks largely to big advances in treating lung tumors.Data presented at the meeting showed progress in combating the second leading cause of death worldwide, Schilsky said. Researchers found medicines used for patients with advanced disease can have an even bigger benefit for those with recently diagnosed tumors, while medicines are emerging that are effective against a wide range of tumors that are driven by specific gene mutations.Deals Getting DoneLarge drugmakers have remained on the prowl for promising cancer therapies that they can acquire through mergers or other transactions. Even Gilead Sciences Inc., which has been in the headlines because of its potential coronavirus treatment remdesivir, has been getting cancer-focused deals done against the backdrop of the pandemic.Last week, Gilead agreed to work on immunotherapy drugs with biotech Arcus Biosciences Inc. And earlier this year it agreed to buy cancer-drug maker Forty Seven for $4.9 billion. Gilead has been pressured by investors to find new drugs that can take the place of some of its aging blockbusters. It made another big bet on cancer when it bought Kite Pharma and its drug Yescarta, though sales of the highly priced genetic therapy have so far failed to live up to expectations.At ASCO, Gilead presented encouraging new data on magrolimab, an immunology drug that was developed by Forty Seven, a sign that the company’s wager could pay off. Gilead’s management is successfully building a pipeline of potential new therapies, Jefferies & Co. analyst Michael Yee said in a note sent to clients.Gilead shares dropped 1.5% early Monday. They now have gained about 20% so far this year, in part because of excitement over remdesivir.Breakthroughs at ASCO could make smaller companies enticing to Gilead and to other giants looking to add to their rosters of experimental therapies. Adaptimmune Therapeutics Plc’s U.S.-traded shares more than doubled in value after the company presented early studies for therapies that could treat a number of cancers, including lung and head and neck tumors.Allogene Therapeutics Inc., which is developing a CAR-T therapy similar to Yescarta, gained 3.5% Friday after it said its treatment benefited 63% of patients with blood cancer in an early-stage trial. Allogene’s founders ran Kite Pharma before selling it to Gilead for $11 billion in 2017.Dueling GiantsLike Gilead, Bristol-Myers Squibb Co. has also sought to refashion itself into a cancer-fighting juggernaut, mostly notably with its $74 billion takeover of Celgene Corp. last year. Even before that transaction, the company was locked in a battle with rival Merck & Co. for supremacy in the market for lung-cancer immunotherapies.Merck’s Keytruda and Bristol-Myers’s Opdivo are blockbusters for each company, and the drugmakers have raced to expand their use in a range of tumor types. But at ASCO, a study of Opdivo in combination with another Bristol-Myers drug, Yervoy, supported what JPMorgan Chase & Co. analyst Chris Schott said in a note was a “niche role” in treating certain lung-cancer patients -- not one that will upset Keytruda’s dominance.Bristol-Myers shares declined 0.2% on Friday, while Merck advanced 2.1%. Both were little changed before U.S. markets opened Monday.Last year, Opdivo generated $7.2 billion in revenue for Bristol-Myers, while Yervoy brought in $1.5 billion. Together, the two drugs accounted for roughly a third of the company’s sales. Meanwhile, Keytruda generated $11 billion for Merck, about 24% of its sales.Another challenge to Keytruda may come from Switzerland’s cancer titan Roche Holding AG. The drugmaker presented data at ASCO showing that combining the experimental tiragolumab with one of its proven medicines, Tecentriq, worked better than prescribing Tecentriq alone in patients with metastatic non-small-cell lung cancer. The phase 2 data suggests it “could potentially compete with Merck’s Keytruda in a segment of lung-cancer patients,” wrote Cinney Zhang of Bloomberg Intelligence.Some Chinese drugmakers also showed promising findings in liver cancer. A combination from Innovent Biologics Inc. showed initial efficacy comparable to Roche in hepatocellular carcinoma, for which China accounts for almost than half of new cases. Innovent shares surged 10% in Hong Kong trading Monday.(Updates with share moves for Pfizer, Gilead and Innovent in eighth, 14th and last paragraphs)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Bristol-Myers Deserves Better Than a Single-Digit Multiple

    Bristol-Myers Deserves Better Than a Single-Digit Multiple

    The company produced expectation-beating results. The acquisition of Celgene has gone very well, but shares trade with a multiple of less than 10 times earnings Continue reading...

  • The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight

    The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight

    Biotech stocks could not sustain the uptrend in the holiday-shortened week, even as traders digested COVID-19-related news flow, clinical readouts, ASCO presentations and a few FDA approvals.Arca Biopharma Inc (NASDAQ: ABIO) was the best performing biotech stock of the week, as it rallied in reaction to an announcement from the company regarding testing of its pipeline asset for COVID-19-associated coagulopathy.The week also saw Merck & Co., Inc. (NYSE: MRK) taking a giant leap of faith into the COVID fray after remaining non-committal thus long.Here are the key catalysts for the unfolding week.Conferences Jefferies Virtual Healthcare Conference: June 2-4 European Academy of Allergy and Clinical Immunology, or EAACI, Digital Conference 2020: June 6-8PDUFA Dates The FDA is set to rule on Menlo Therapeutics Inc's (NASDAQ: MNLO) FMX103 - 1.5% minocycline foam -, which came into its stable via its Foamix acquisition, as a treatment option for moderate-to-severe papulopustular rosacea. (Tuesday)Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and AbbVie Inc (NYSE: ABBV) await FDA verdict on the latter's NDA for elagolix, which is being evaluated for treating uterine fibroids. (likely on Thursday)Merck's sNDA for its triple combo antibiotic Recarbrio has a PDUFA date of June 6.See Also: PhaseBio Analyst Says Coronavirus Study Creates Near-Term CatalystClinical Readouts ASCO 2020 Annual Meeting (presentations during the plenary session scheduled for Sunday)View more earnings on IBBAstraZeneca plc (NYSE: AZN) is scheduled to present detailed results from the Phase 3 ADAURA trial of its Tagrisso in early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.Merck will present results of a Phase 3 study evaluating Keytruda as a first-line treatment of patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer.EAACI Digital Conference Presentations Celldex Therapeutics, Inc. (NASDAQ: CLDX) will make a late-breaking poster presentation of data from the Phase 1 healthy volunteer study of its KIT inhibitor, CDX-0159.Standalone Releases Replimune Group Inc (NASDAQ: REPL) is scheduled to provide updated Phase 1/2 data from patients with melanoma and non-melanoma skin cancers treated with RP1 combined with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo. (Wednesday)Earnings Protalix Biotherapeutics Inc (NYSE: PLX) (Monday, before the market open)IPO Legend Biotech, a clinical-stage biotech engaged in the discovery and development of novel cell therapies for oncology and other indications, has filed to offer 18.425 million ADSs in an IPO, with each ADS representing two ordinary shares. The company expects the IPO to be priced between $18 and $20. It has applied to list its ADSs on the Nasdaq under the ticker symbol "LEGN."California-based Pliant Therapeutics, Inc. is planning a 6-million share offering to be priced between $14 and $16. The clinical-stage biopharma focused on discovering and developing novel therapies for the treatment of fibrosis has applied to list its shares on the Nasdaq under the ticker symbol "PLRX."IPO Quiet Period Expiry Ayala Pharmaceuticals Inc (NASDAQ: AYLA)See more from Benzinga * The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant * The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer * The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas(C) 2020 Benzinga does not provide investment advice. All rights reserved.

  • Merck's Keytruda Better Than Chemotherapy for Certain Colon Cancers
    Motley Fool

    Merck's Keytruda Better Than Chemotherapy for Certain Colon Cancers

    Keytruda reduced the risk of disease progression or death by 40% compared to chemotherapy. Put another way, patients treated with Keytruda lived for 16.5 months without their tumors starting to grow, compared to 8.2 months for patients treated with chemotherapy.

  • Reuters

    European agency panel recommends approval of J&J's Ebola vaccine

    A panel of the European health regulator on Friday recommended approving Johnson & Johnson's two-dose experimental vaccine for Ebola in the European Union. J&J submitted its application to the European Medicines Agency (EMA) in November for its vaccine, which targets an Ebola strain that causes the virus in most people. The company in February said it was developing a coronavirus vaccine program that would utilize the same technologies used to make the experimental Ebola vaccine.

  • Now’s the Time to Buy These 3 Stocks
    Motley Fool

    Now’s the Time to Buy These 3 Stocks

    What investor doesn't want to own a solid company with exciting prospects for business growth in the near- and mid-term? Here we explore a few interesting opportunities ranging from a big pharma name to a pre-revenue biotech. If you want a solid stock that allows you to sleep soundly at night, buy Merck (NYSE: MRK).

  • Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer
    Business Wire

    Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer

    Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer

  • MarketWatch

    Merck, Pfizer share gains contribute to Dow's 86-point climb

    DOW UPDATE Shares of Merck and Pfizer are trading higher Thursday afternoon, sending the Dow Jones Industrial Average into positive territory. Shares of Merck (MRK) and Pfizer (PFE) are contributing to the blue-chip gauge's intraday rally, as the Dow (DJIA) is trading 86 points, or 0.